Treating depression in older adults can be challenging, especially when first-line therapies fail. We review evidence-based strategies for treatment-resistant depression, from medication adjustments and augmentation to neuromodulation and lifestyle interventions.

Long-acting buprenorphine is a promising new treatment for opioid use disorder, but it usually requires a seven-day stabilization period before initiation. Here, researchers develop and evaluate a novel protocol for initiating long-acting injectable buprenorphine in a single day. The trial is small, but results are promising.

By successfully completing the test you will be awarded a certificate for 2 CME credit.

The FDA recently approved donanemab for early Alzheimer’s, offering new hope by slowing cognitive decline.

This umbrella review looked at modifiable risk factors for late life depression—and only two stood out. 

For years, moderate drinking was seen as harmless or even beneficial. This study challenges that, revealing how even modest alcohol consumption can raise brain iron levels and impair cognitive function.